These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8794364)

  • 21. Biochemical characterization of HIV-1 reverse transcriptases encoding mutations at amino acid residues 161 and 208 involved in resistance to phosphonoformate.
    Tramontano E; Piras G; Mellors JW; Putzolu M; Bazmi HZ; La Colla P
    Biochem Pharmacol; 1998 Dec; 56(12):1583-9. PubMed ID: 9973178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine.
    Kong XB; Zhu QY; Ruprecht RM; Watanabe KA; Zeidler JM; Gold JW; Polsky B; Armstrong D; Chou TC
    Antimicrob Agents Chemother; 1991 Oct; 35(10):2003-11. PubMed ID: 1722077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.
    Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2002 Sep; 76(18):9143-51. PubMed ID: 12186898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
    Harrigan PR; Kinghorn I; Bloor S; Kemp SD; Nájera I; Kohli A; Larder BA
    J Virol; 1996 Sep; 70(9):5930-4. PubMed ID: 8709214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors.
    Larder BA
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2664-9. PubMed ID: 1282792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants.
    Arts EJ; Quiñones-Mateu ME; Albright JL; Marois JP; Hough C; Gu Z; Wainberg MA
    J Virol; 1998 Jun; 72(6):4858-65. PubMed ID: 9573252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase.
    Arion D; Kaushik N; McCormick S; Borkow G; Parniak MA
    Biochemistry; 1998 Nov; 37(45):15908-17. PubMed ID: 9843396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.
    Kisic M; Mendieta J; Puertas MC; Parera M; Martínez MA; Martinez-Picado J; Menéndez-Arias L
    J Mol Biol; 2008 Oct; 382(2):327-41. PubMed ID: 18662701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.
    Harrigan PR; Bloor S; Larder BA
    J Virol; 1998 May; 72(5):3773-8. PubMed ID: 9557659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypersusceptibility to substrate analogs conferred by mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Smith RA; Anderson DJ; Preston BD
    J Virol; 2006 Jul; 80(14):7169-78. PubMed ID: 16809322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.
    Hu Z; Giguel F; Hatano H; Reid P; Lu J; Kuritzkes DR
    J Virol; 2006 Jul; 80(14):7020-7. PubMed ID: 16809307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215.
    Chamberlain PP; Ren J; Nichols CE; Douglas L; Lennerstrand J; Larder BA; Stuart DI; Stammers DK
    J Virol; 2002 Oct; 76(19):10015-9. PubMed ID: 12208978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.
    Prado JG; Franco S; Matamoros T; Ruiz L; Clotet B; Menéndez-Arias L; Martínez MA; Martinez-Picado J
    Virology; 2004 Aug; 326(1):103-12. PubMed ID: 15262499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1.
    García-Lerma JG; Gerrish PJ; Wright AC; Qari SH; Heneine W
    J Virol; 2000 Oct; 74(20):9339-46. PubMed ID: 11000201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
    Larder BA; Kohli A; Bloor S; Kemp SD; Harrigan PR; Schooley RT; Lange JM; Pennington KN; St Clair MH
    J Virol; 1996 Sep; 70(9):5922-9. PubMed ID: 8709213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
    Miranda LR; Götte M; Liang F; Kuritzkes DR
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.
    Gobert JM; Remington KM; Zhu YQ; North TW
    Antimicrob Agents Chemother; 1994 Apr; 38(4):861-4. PubMed ID: 8031060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA; Kellam P; Kemp SD
    Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and antiviral evaluation of SATE-foscarnet prodrugs and new foscarnet-AZT conjugates.
    Meier C; Aubertin AM; de Monte M; Faraj A; Sommadossi JP; Périgaud C; Imbach JL; Gosselin G
    Antivir Chem Chemother; 1998 Jan; 9(1):41-52. PubMed ID: 9875376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.